Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004329 · ClinicalTrials.gov registry record
Study of Alpha-2 Adrenergic Receptor Dysfunction in Regional Lipoatrophy
A clinical trial, sponsored by National Center for Research Resources (NCRR).
- Completed
- Registry status
- 12
- Enrollment target
NCT00004329 is a clinical trial that has completed, run by National Center for Research Resources (NCRR). The registered enrollment target is 12 participants.
The verdict
NCT00004329 has completed, sponsored by National Center for Research Resources (NCRR).
- COMPLETED
- Registry status
- 12 participants
- Enrollment target
Study Summary
OBJECTIVES: I. Determine the response in plasma norepinephrine concentration and plasma glycerol to the agonist (clonidine) and the antagonist (yohimbine) of the alpha-2 adrenergic receptor in 6 patients with regional lipoatrophy and in 6 controls. II. Determine the full sequence of the alpha-2 adrenergic receptor structural gene in genomic DNA from peripheral blood leukocytes.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 1999-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004329
The ClinicalTrials.gov registry entry for NCT00004329 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Center for Research Resources (NCRR), which has 94 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00004329 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004329 about?
NCT00004329 is a clinical study titled "Study of Alpha-2 Adrenergic Receptor Dysfunction in Regional Lipoatrophy". OBJECTIVES: I. Determine the response in plasma norepinephrine concentration and plasma glycerol to the agonist (clonidine) and the antagonist (yohimbine) of the alpha-2 adrenergic receptor in 6 patients with regional lipoatrophy and in 6 controls. II. Determine the full sequence of the alpha-2 adr...
What is the current status of trial NCT00004329?
This trial is currently completed. The enrollment target is 12 participants. The study started on 1999-11.
Who is sponsoring clinical trial NCT00004329?
This trial is sponsored by National Center for Research Resources (NCRR), which has 94 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.